These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26131691)

  • 1. Methotrexate Is a JAK/STAT Pathway Inhibitor.
    Thomas S; Fisher KH; Snowden JA; Danson SJ; Brown S; Zeidler MP
    PLoS One; 2015; 10(7):e0130078. PubMed ID: 26131691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms.
    Thomas S; Fisher K; Snowden J; Danson S; Brown S; Zeidler M
    Lancet; 2015 Feb; 385 Suppl 1():S98. PubMed ID: 26312921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
    Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
    J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Genetic Screen Reveals an Unexpected Role for Yorkie Signaling in JAK/STAT-Dependent Hematopoietic Malignancies in
    Anderson AM; Bailetti AA; Rodkin E; De A; Bach EA
    G3 (Bethesda); 2017 Aug; 7(8):2427-2438. PubMed ID: 28620086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How does methotrexate work?
    Alqarni AM; Zeidler MP
    Biochem Soc Trans; 2020 Apr; 48(2):559-567. PubMed ID: 32239204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gα73B is a downstream effector of JAK/STAT signalling and a regulator of Rho1 in Drosophila haematopoiesis.
    Bausek N; Zeidler MP
    J Cell Sci; 2014 Jan; 127(Pt 1):101-10. PubMed ID: 24163435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
    Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
    Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
    Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
    Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification and characterization of a STAT5 gene signature in hematologic malignancies.
    Sonkin D; Palmer M; Rong X; Horrigan K; Regnier CH; Fanton C; Holash J; Pinzon-Ortiz M; Squires M; Sirulnik A; Radimerski T; Schlegel R; Morrissey M; Cao ZA
    Cancer Biomark; 2015; 15(1):79-87. PubMed ID: 25524945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary.
    Sutherland JM; Frost ER; Ford EA; Peters AE; Reed NL; Seldon AN; Mihalas BP; Russel DL; Dunning KR; McLaughlin EA
    Mol Hum Reprod; 2018 Nov; 24(11):533-542. PubMed ID: 30247637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity.
    Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA
    Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.
    Baldini C; Moriconi FR; Galimberti S; Libby P; De Caterina R
    Eur Heart J; 2021 Nov; 42(42):4389-4400. PubMed ID: 34343257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The many faces of Janus kinase.
    Seavey MM; Dobrzanski P
    Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
    Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
    Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.